Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wubben, Thomas
NCT04671433 / 2020-002873-88: Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene	Completed	3	97	Europe, Canada, US, RoW	Genetic: AAV5-hRKp.RPGR, botaretigene sparoparvovec	Janssen Research & Development, LLC, Janssen Research & Development, LLC	X-Linked Retinitis Pigmentosa	09/24	09/24
MGT-RPGR-022, NCT04794101 / 2020-002255-37: Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene	Active, not recruiting	3	97	Europe, Canada, US, RoW	Genetic: AAV5-hRKp.RPGR Intermediate Dose, botaretigene sparoparvovec, Genetic: AAV5-hRKp.RPGR Low Dose	Janssen Research & Development, LLC, Janssen Research & Development, LLC	X-Linked Retinitis Pigmentosa	09/29	12/29
NCT04312672 / 2018-000425-31: Long-term Follow-up Gene Therapy Study for RPGR- XLRP	Active, not recruiting	1/2	42	Europe, US	AAV5-hRKp.RPGR	Janssen Research & Development, LLC, MeiraGTx UK II Ltd, Janssen Research & Development, LLC	X-Linked Retinitis Pigmentosa	11/26	11/26